Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

baxter a/s - glucosemonohydrat, kaliumchlorid, magnesiumchloridhexahydrat, natriumacetattrihydrat, natriumchlorid, natriumgluconat - infusionsvæske, opløsning - 50 mg/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - arthritis, reumatoid - immunosuppressiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

csl behring gmbh - koagulationsfaktor xiii, humant - pulver og solvens til injektions- /infusionsvæske, opløsning - 250 ie

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

fresenius kabi ab - calciumchloriddihydrat, kaliumchlorid, magnesiumchloridhexahydrat, natriumacetattrihydrat, natriumchlorid - infusionsvæske, opløsning

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

hameln pharma gmbh - oxycodonhydrochlorid - injektions-/infusionsvæske, opløsning - 10 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

hameln pharma gmbh - lacosamid - infusionsvæske, opløsning - 10 mg/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressiva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

grünenthal gmbh - esomeprazolnatrium - pulver til injektions-/infusionsvæske, opløsning - 40 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

grifols deutschland gmbh - alfa-1 proteinaseinhibitor, humant - pulver og solvens til infusionsvæske, opløsning - 1000 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

aristo pharma gmbh - voriconazol - pulver til infusionsvæske, opløsning - 200 mg